Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files

Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity. The National Cancer Institute (NCI) Experimental Therapeutics Program has accepted four radiopharmaceutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Capala, Jacek, Ivy, Susan Percy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611355/
https://www.ncbi.nlm.nih.gov/pubmed/31316916
http://dx.doi.org/10.3389/fonc.2019.00573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611355/
https://www.ncbi.nlm.nih.gov/pubmed/31316916
http://dx.doi.org/10.3389/fonc.2019.00573

Ejemplares similares